GSE139261 PDX SOX10 overexpression G144 2 v 3 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE139261_PDX_SOX10 overexpression_G144_2_v_3_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE139261_PDX_SOX10 overexpression_G144_2_v_3_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE139261_PDX_SOX10 overexpression_G144_2_v_3_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE139261_PDX_SOX10 overexpression_G144_2_v_3_human_up.

Results found

Linked to

 

Label

Description

 

Gene

RNA polymerase II subunit J3

Gene

ZNF747 divergent transcript

Gene

MORC2 antisense RNA 1

Gene

ribosomal protein L17 pseudogene

Gene

NRXN1 divergent transcript

Gene

WDR45-like pseudogene

Gene

ribosomal protein S2 pseudogene 34

Gene

ribosomal protein L21 pseudogene 60

Gene

ribosomal protein L34 pseudogene 6

Gene

uncharacterized LOC124901872

  • Gene

    RNA polymerase II subunit J3


  • Gene

    ZNF747 divergent transcript


  • Gene

    MORC2 antisense RNA 1


  • Gene

    ribosomal protein L17 pseudogene


  • Gene

    NRXN1 divergent transcript


  • Gene

    WDR45-like pseudogene


  • Gene

    ribosomal protein S2 pseudogene 34


  • Gene

    ribosomal protein L21 pseudogene 60


  • Gene

    ribosomal protein L34 pseudogene 6


  • Gene

    uncharacterized LOC124901872

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.